CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

YESCARTA

YESCARTANeutral
AI Analysis

Summary

This is a routine indication statement for YESCARTA (axicabtagene ciloleucel), a CAR-T cell therapy for adult patients with large B-cell lymphoma with specific treatment-resistant characteristics.

Importance:1/10
Sentiment:
0.00
CAR-T therapyoncologylymphomacell therapy
Related Companies

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on August 7, 2026 12:33 PM

Read Original